Project Grant R21CA297430
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $479K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,486 to Yale University to elucidate the mechanisms underlying the progression of non-small cell lung cancer (NSCLC) to leptomeningeal disease (LMD). The primary objectives are to identify the pathophysiological mechanisms driving the progression to LMD, particularly in cases of EGFR-mutant NSCLC that become resistant to tyrosine kinase inhibitor (TKI) treatment. The research...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to Harvard T.H. Chan School of Public Health to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer. The research aims to leverage multi-omic data (genetics, genomics, transcriptomics, proteomics) from over 80,000 NSCLC...
- The Project Grant award of $424,734 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of a novel spatial proteomics approach to profile immune cell types and their locations within a tumor microenvironment. The University of Illinois, the awardee, aims to integrate 3D microscopy techniques with bottom-up proteomic assays to offer deep proteome profiles of specific immune cells at various subregions of a mouse tumor (Aims 1 and 2). The goal is...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The federal Project Grant award of $472,730.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research at Weill Medical College of Cornell University to elucidate the role of the tumor suppressor KEAP1 in antitumor immunity for non-small cell lung cancer (NSCLC). The research aims to investigate how newly identified upregulated oncoproteins that are potential KEAP1 substrates contribute to the immune-evasive phenotype observed in KEAP1-mutant NSCLCs. The...
- The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon gamma (IFNγ) signaling pathway in the lung tumor microenvironment and its impact on tumor immunity. The project aims to deconvolute how various components of the IFNγ pathway, including the negative regulator SOCS1, influence immune cell infiltration and response to immune...
- This Project Grant award of $124,134 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms of pathogenesis and treatment response in immune checkpoint inhibitor-induced colitis. The research aims to define the role of specific T cell subsets recruited from circulation in promoting inflammation and mediating therapeutic response in this condition, which can occur in up to 40% of cancer patients receiving immune checkpoint...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...